drugset
drugset / Trial / NCT00918931

Obatoclax for Systemic Mastocytosis

NCT00918931 ↗

Phase 2 Terminated 3 enrolled M.D. Anderson Cancer Center Gemin X · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if obatoclax mesylate can help to control systemic mastocytosis. The safety of this drug will also be tested.

Timeline

Start
2009-06
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Obatoclax Small molecule 30 mg Intravenous

Indications

leukemia systemic mastocytosis